Objective: To study the effects of the active components of Xiaoxuming Decoction (XXM), a compound traditional Chinese herbal medicine, on chronic cerebral ischemia in rats.
Methods: Chronic cerebral ischemia was induced in rats by occlusion of bilateral common carotid arteries. Then, the rats with chronic cerebral ischemia were randomly divided into five groups: model group, extract of Ginkgo biloba group and low-, medium- and high-dose active components of XXM groups. Another 11 rats without occlusion of common carotid arteries were used as the sham-operation group. Memory behavior was investigated by Morris water maze test. The structure of hippocampus and cortex neurons was observed with Nissel staining. The white matter lesion was stained with Klüver-Barrera stain method to observe the pathological changes. The astrocyte activation was observed using immunohistochemical method with glial fibrillary acidic protein (GFAP) antibody.
Results: The active components of XXM could significantly improve the impairment of learning and memory induced by chronic cerebral ischemia in rats. Compared with the model group, the time to reach the platform for rats was shortened by treating with the active components of XXM in Morris water maze test, particularly in the medium-dose group (P<0.05). In addition, the low- and medium-dose active components of XXM improved the decrease of cerebrovascular reactivity induced by chronic cerebral ischemia. The results of the pathological analysis also suggested that the active components of XXM could ameliorate the pathological damage induced by chronic cerebral ischemia in rats with the number of neurons increased, and the morphology and distribution of neurons recovered to normal levels. The low-dose active components of XXM significantly reduced the white matter lesions (P<0.05, P<0.01). Active components of XXM treatment could also reduce the activation of astrocytes.
Conclusion: The active components of XXM may attenuate the chronic cerebral ischemic injury in rats.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3736/jcim20120114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and laboratory characteristics of Sjögren's syndrome-associated autoimmune liver disease: a real-world, 10-year retrospective study.
Clin Rheumatol
January 2025
Department of Rheumatology and Immunology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Objectives: To investigate the clinical and laboratory features of Sjögren's syndrome-associated autoimmune liver disease (SS-ALD) patients and identify potential risk and prognostic factors.
Methods: SS patients with or without ALD, who visited Tongji Hospital between the years 2011 and 2021 and met the 2012 American College of Rheumatology (ACR) classification criteria for Sjögren's syndrome, were retrospectively enrolled. The clinical and laboratory data of the enrolled patients, including autoimmune antibodies, were collected and analyzed with principal component analysis, correlation analysis, LASSO regression, and Cox regression.
PMN-MDSCs are responsible for immune suppression in anti-PD-1 treated TAP1 defective melanoma.
Clin Transl Oncol
January 2025
Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510013, Guangdong, China.
Introduction: The transporter associated with antigen processing (TAP) is a key component of the classical HLA I antigen presentation pathway. Our previous studies have demonstrated that the downregulation of TAP1 contributes to tumor progression and is associated with an increased presence of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. However, it remains unclear whether the elevation of MDSCs leads to immune cell exhaustion in tumors lacking TAP1.
View Article and Find Full Text PDFDihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing.
Cancer Chemother Pharmacol
January 2025
Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Purpose: Patients with partial or complete DPD deficiency have decreased capacity to degrade fluorouracil and are at risk of developing toxicity, which can be even life-threatening.
Case: A 43-year-old man with moderately differentiated rectal adenocarcinoma on capecitabine presented to the emergency department with complaints of nausea, vomiting, diarrhea, weakness, and lower abdominal pain for several days. Laboratory findings include grade 4 neutropenia (ANC 10) and thrombocytopenia (platelets 36,000).
X-ray Responsive Antioxidant Drug-Free Hydrogel for Treatment of Radiation Skin Injury.
ACS Appl Mater Interfaces
January 2025
State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, P. R. China.
Radiotherapy (RT) is widely applied in tumor therapy, but inevitable side effects, especially for skin radiation injury, are still a fatal problem and life-threatening challenge for tumor patients. The main components of topical radiation protection preparations currently available on the market are antioxidants, such as SOD, which are limited by their unstable activity and short duration of action, making it difficult to achieve the effects of radiation protection and skin radiation damage treatment. Therefore, we designed a drug-free antioxidant hydrogel patch with encapsulated bioactive epidermal growth factor (EGF) for the treatment of radiation skin injury.
View Article and Find Full Text PDFStrategies for introducing and implementing vaccines for adults into national immunization programs in Europe: Good practices and key insights of the adult immunization board meeting.
Hum Vaccin Immunother
December 2025
Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium.
In April 2024, the Adult Immunization Board convened a technical meeting to explore the latest strategies and identify exemplary approaches regarding the implementation of vaccines for adults into Europe's National Immunization Programs (NIPs). The meeting was built around three pillars: decision making for introducing a new vaccine, implementation, monitoring, and evaluation. The increasing number of new vaccines available in a context of competing health priorities warrants transparent and evidence-based decision-making processes for vaccine introduction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!